PAVmed Inc is a medical device company engaged in advancing a pipeline of medical technologies from concept to commercialization using a business model focused on capital and time efficiency. Its product includes EsoCheck; CarpX; EsoGuard; PortIO; DisappEAR and others. PAVmed Inc is a medical device company engaged in advancing a pipeline of medical technologies from concept to commercialization using a business model focused on capital and time efficiency. Its product includes EsoCheck; CarpX; EsoGuard; PortIO; DisappEAR and others.
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire NEW YORK, Jan. 13, 2025 Quarterly test volume of over 4,000 tests represented sequential increase of 45 percent NEW...
Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule PR Newswire NEW YORK, Dec. 23, 2024 NEW YORK, Dec. 23, 2024 /PRNewswire/ -- Lucid...
Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters PR Newswire NEW YORK, Dec. 19, 2024 Partnership launched with fully-contracted...
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication PR Newswire NEW YORK, Dec. 11, 2024 Study demonstrates outstanding...
Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones PR Newswire NEW YORK, Dec. 3, 2024 New convertible debt...
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test PR Newswire NEW YORK, Nov. 20, 2024 NEW YORK, Nov. 20, 2024 /PRNewswire/...
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum PR Newswire NEW YORK, Nov. 18, 2024 NEW YORK, Nov. 18, 2024 /PRNewswire/...
PAVmed Provides Business Update and Third Quarter 2024 Financial Results PR Newswire NEW YORK, Nov. 14, 2024 Lucid reports record quarterly EsoGuard® revenue and completes clinical evidence...
Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication PR Newswire NEW YORK, Nov. 7...
Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers PR Newswire NEW YORK, Nov. 5, 2024 Industry veterans from leading cancer...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.019 | -2.88315629742 | 0.659 | 0.68 | 0.5719 | 245149 | 0.63644287 | CS |
4 | -0.03 | -4.4776119403 | 0.67 | 0.76 | 0.5719 | 245348 | 0.64694591 | CS |
12 | -0.39 | -37.8640776699 | 1.03 | 1.25 | 0.5719 | 175926 | 0.74165328 | CS |
26 | -0.36 | -36 | 1 | 1.9 | 0.5719 | 112344 | 0.87287307 | CS |
52 | -1.69 | -72.5321888412 | 2.33 | 3.5 | 0.5719 | 88822 | 1.20982396 | CS |
156 | -22.76 | -97.264957265 | 23.4 | 35.1 | 0.5719 | 580730 | 14.05860404 | CS |
260 | -21.56 | -97.1171171171 | 22.2 | 145.5 | 0.5719 | 1148112 | 47.88176448 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約